Costs associated with severe and nonsevere systemic lupus erythematosus in canada

Arthritis Care and Research

Volumn 67, Issue 3, 2015, Pages 431-436

  Clarke, Ann E ^a   Urowitz, Murray B ^b   Monga, Neerav ^c   Hanly, John G ^d  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c GLAXOSMITHKLINE   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ADULT; ARTICLE; CANADA; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; MEDICAL SPECIALIST; MIDDLE AGED; REHABILITATION CARE; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; ECONOMICS; HEALTH CARE PLANNING; LUPUS ERYTHEMATOSUS, SYSTEMIC; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME; UTILIZATION; YOUNG ADULT;

ADULT; CANADA; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; LINEAR MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MODELS, ECONOMIC; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 84923313251     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22452     Document Type: Article

References (15)

1. Zhu TY, Tam LS, Li EK. Cost-of-illness studies in systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken) 2011;63:751-60.
2. Slawsky KA, Fernandes AW, Fusfeld L, Manzi S, Goss TF. A structured literature review of the direct costs of adult systemic lupus erythematosus in the US. Arthritis Care Res (Hoboken) 2011;63:1224-32.
3. Clarke A, Petri M, Manzi S, Isenberg D, Gordon C, Senecal JL, et al. An international perspective on the well being and health care costs for patients with systemic lupus erythematosus. J Rheumatol 1999;26:1500-11.
4. Clarke AE, Esdaile JM, Bloch DA, Lacaille D, Danoff DS, Fries JF. A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs. Arthritis Rheum 1993;36:1548-59.
5. Aghdassi E, Zhang W, St-Pierre Y, Clarke A, Morrison S, Peeva V, et al. Healthcare cost and loss of productivity in a Canadian population of patients with and without lupus nephritis. J Rheumatol 2011;38:658-66.
6. Clarke A, Panopalis P, Petri M, Manzi S, Isenberg D, Gordon C, et al. SLE patients with renal damage incur higher health care costs. Rheumatology (Oxford) 2008;47:329-33.
7. Zhu T, Tam L, Lee V, Lee K, Li E. Systemic lupus erythematosus with neuropsychiatric manifestation incurs high disease costs: a cost-of-illness study in Hong Kong. Rheumatology (Oxford) 2009;48:564-8.
8. Doria A, Amoura Z, Cervera R, Khamastha M, Schneider M, Richter J, et al. Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann Rheum Dis 2014;73:154-60.
9. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
10. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
11. Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999;8:685-91.
12. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J Rheumatol 2000;27:373-6.
13. Garris C, Jhingran P, Bass D, Engel-Nitz NM, Riedel A, Dennis G. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan. J Med Econ 2013;16:667-77.
14. Furst DE, Clarke A, Fernandes AW, Bancroft T, Gajria K, Greth W, et al. Resource utilization and direct medical costs in adult systemic lupus erythematosus patients from a commercially insured population. Lupus 2013;22:268-78.
15. Panopalis P, Yazdany J, Gillis JZ, Julian L, Trupin L, Hersh AO, et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum 2008;59:1788-95.